Slide 1: Q4 2022 Results Investor Presentation
Company overview Financial review 2023 priorities Appendix Q4 2022 Results Investor presentation 1 Investor Relations │ Q4 2022 Results
Slide 2: Disclaimer
Company overview Financial review 2023 priorities Appendix Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “pl
Slide 3: Company overview
Company Company overview overview Financial review 2023 priorities Appendix Vas Narasimhan, M.D. Chief Executive Officer Company overview 3 NOVARTIS Q4 RESULTS | FEBRUARY 1, 2023 | NOVARTIS MEDIA PRESENTATION 3 Investor Relations │ Q4 2022 Results
Slide 4: Robust core operating income growth and core margin expansion; important innovation milestones
Company Company overview overview Financial review 2023 priorities Appendix STRATEGY Novartis delivers robust core operating income growth and core margin expansion; achieves important innovation milestones Growth, cc 1 Innovation 3 Group sales Q4 +3% (FY +4%) Pluvicto EU approval for mCRPC post-tax
Slide 5: New Novartis: Our focused strategy
Company Company overview overview Financial review 2023 priorities Appendix STRATEGY New Novartis1: Our focused strategy Focusing on high-value innovative medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches Our focus Our priori
Slide 6: Pure-play Innovative Medicines company positioned to leverage scale
Company Company overview overview Financial review 2023 priorities Appendix STRATEGY As a pure-play Innovative Medicines company, New Novartis is uniquely positioned to leverage its scale, strengths and expertise Novartis is on track to become a pure-play Simplified organizational model allowing for
Slide 7: New Novartis expected to continue delivering improved financials
Company Company overview overview Financial review 2023 priorities Appendix STRATEGY New Novartis expected to continue delivering improved financials New Novartis expectations (illustrative only) Incremental benefit from planned Sandoz spin-off Expected to grow sales, core margin Sales Free Cash Flo
Slide 8: Focused on five core Therapeutic Areas
Company Company overview overview Financial review 2023 priorities Appendix STRATEGY Focused on five core Therapeutic Areas that have the largest growth potential and leverage our existing assets/expertise Select examples1 Cardiovascular Immunology Neuroscience Solid Tumors Hematology Disease § Hear
Slide 9: Shareholder-focused capital allocation priorities
Company Company overview overview Financial review 2023 priorities Appendix STRATEGY Our capital allocation priorities are shareholder-focused, allowing for flexibility in strategic investments and capital distribution Investing in the business Returning to shareholders USD 59bn distributed 2018-202
Slide 10: Prioritizing pipeline to high-value innovative medicines
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION Prioritizing pipeline to high-value innovative medicines Refining our proven development engine with greater focus on asset value and improving R&D productivity Proven development engine Improving R&D productivity
Slide 11: Key near-term readouts (2023) for high-value medicines
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION Key near-term readouts (2023) for high-value medicines... Key assets* with submission enabling readouts in 2023 Kisqali® Iptacopan Pluvicto® NATALEE trial in adjuvant breast APPOINT-PNH trial in treatment- PSMAfor
Slide 12: Readouts set to increase in 2024-2025
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION ... set to increase in 2024-2025 timeframe Key assets* with submission enabling readouts in 2024-2025 Pelacarsen Pluvicto® OAV-101 CVRR mHSPC SMA IT Readout and submission in 2025 Readout and submission in 2024 Re
Slide 13: Kisqali NATALEE study continues following first interim analysis
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION Kisqali® – NATALEE study continues following first interim analysis; final readout expected H2 2023 NATALEE: HR+/HER2- pre- and post-menopausal, early breast cancer Stage II & III | N=5000 3 weeks on/1 week off NA
Slide 14: Pluvicto PSMAfore study demonstrated rPFS benefit; filing H2 2023
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION Pluvicto® – PSMAfore study demonstrated statistically significant and clinically meaningful radiographic PFS benefit; filing H2 2023 PSMAfore: Patients with mCRPC who progressed while on ARPI treatment | N=450 rPF
Slide 15: Expanding Pluvicto development program in earlier prostate cancer
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION Expanding Pluvicto® development program to address significant unmet need in earlier lines and stages of prostate cancer Our ongoing clinical development plan for Pluvicto® in prostate cancer Prostate cancer incid
Slide 16: Iptacopan across multiple complement-driven conditions
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION Iptacopan – provides the opportunity to redefine care across multiple complement-driven conditions1 First-in-class, oral, selective factor B inhibitor, targeting complement system proximally via alternative pathwa
Slide 17: Iptacopan superior to anti-C5 in PNH with residual anemia
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION Iptacopan demonstrated superiority over anti-C5 in adult PNH patients with residual anemia despite anti-C5 treatment... APPLY-PNH: Randomized, active-comparator controlled Ph3 trial in adult PNH patients with resi
Slide 18: Iptacopan increases Hb in treatment-naive PNH patients
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION ... and showed clinically meaningful increases in Hb levels for treatment-naive adult patients with PNH APPOINT-PNH: Single-arm Ph3 trial in adult patients with PNH with hemolysis (LDH > 1.5x ULN) and anemia (Hb <
Slide 19: Upcoming 9 months analysis from IgAN Ph3 study APPLAUSE
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION Upcoming 9 months analysis from IgAN Ph3 study (APPLAUSE) could potentially support US Subpart H filing APPLAUSE-IgAN: Biopsy-confirmed patients with IgAN at risk of progression with elevated proteinuria (UPCR1 ≥1
Slide 20: Selected early stage assets with high-impact potential
Company Company overview overview Financial review 2023 priorities Appendix INNOVATION Selected early stage assets with the potential to deliver high-impact medicines for patients Compound Therapeutic area MoA Indication(s) Current phase Next milestone XXB750 Cardiovascular NPR1 agonist Hypertension
Slide 21: Confidence in near and mid-term growth underpinned by multi-bn medicines
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Confidence in near and mid-term growth underpinned by multi-bn existing medicines and pipeline Select pipeline with multi-bn1 potential Additional multi-bn1 medicines Existing large multi-bn medicines1, remibrutinib U
Slide 22: Company overview
Company Company overview overview Financial review 2023 priorities Appendix 22 Investor Relations │ Q4 2022 Results
Slide 23: Entresto delivers strong growth across all geographies
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Entresto® delivers strong growth across all geographies Sales evolution US weekly TRx2 USD m, % cc Total prescriptions (000) Ex-US US Strong Q4 momentum across geographies 100 US: NBRx +16% vs PY, ~1.2m TRx in Q41 +44
Slide 24: Cosentyx Q4 sales impacted by revenue deduction true-up
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Cosentyx® Q4 sales impacted mainly by a revenue deduction true-up related to prior quarters in the US and China COVID lockdowns Sales evolution USD m, % cc Ex-US US Q4 performance US: -18%/-6%1. Impacted by a RD true-
Slide 25: Cosentyx life cycle management to drive growth from 2024
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Cosentyx® – life cycle management to drive growth from 2024 Peak sales potential including all existing and new indications > USD 7bn Indication Potential Life cycle development milestones Hidradenitis Suppurativa (HS
Slide 26: Kesimpta shows strong growth
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Kesimpta® shows strong growth driven by a compelling product profile Sales evolution USD m, % cc Ex-US US Global sales +28% (cc) vs. Q3, driven by US1 TRx +116% vs. PY (market +1%)1,2 369 NBRx +43% vs. PY (market -8%)
Slide 27: Kisqali delivers strong growth across all geographies
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Kisqali® delivers strong growth across all geographies based on increasing recognition of overall survival and quality of life benefits Sales evolution US mBC NBRx share1 USD m, % cc R3M, % FY sales USD 1.2bn (+38% cc
Slide 28: Zolgensma maintains leading share in SMA patients under 2 years
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Zolgensma® maintains leading share in patients with SMA <2 years of age1; Q4 growth impacted by prior year prevalent boluses Sales evolution USD m, % cc Ex-US US Markets mainly incident patient population +5% Maintain
Slide 29: Leqvio continuing to progress the launch
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Leqvio® – we are continuing to progress the launch in Q4... Addressing non-clinical barriers Access Adherence FY sales USD 112 million Patients covered at or near label1 Patients coming for 2nd dose within <95 days4 O
Slide 30: Expect steady Leqvio ramp in 2023
Company Company overview overview Financial review 2023 priorities Appendix GROWTH ... expect steady ramp in 2023 similar to Entresto® US trajectory Leqvio® in line with initial Entresto® launch 2023 focus US monthly sales evolution USD m US: Accelerate adoption Leqvio ® Entresto ® Enable new facili
Slide 31: Pluvicto rapid uptake in US
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Pluvicto® rapid uptake in US reflects very strong demand, driven by significant unmet need and impressive clinical profile Sales evolution Global sales, USD m FY sales USD 271 million (almost entirely US) NBRx share 1
Slide 32: Pluvicto manufacturing capacity set to expand in 2023
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Pluvicto® manufacturing capacity is set to significantly expand in 2023 with bringing Millburn and Indianapolis on-line Expected coverage by end 2023 Manufacturing site1: Ivrea Millburn Indianapolis Zaragoza Commercia
Slide 33: Scemblix launch off to a strong start
Company Company overview overview Financial review 2023 priorities Appendix GROWTH Scemblix® launch off to a strong start Sales evolution USD m Ex-US US FY sales USD 149 million US sales driven by patients resistant/intolerant to other 52 TKIs; CML 3L+ NBRx share at 29%1 10 41 4 Global rollout ongoi
Slide 34: Financial review and 2023 guidance
Company overview Financial review Financial review 2023 priorities Appendix Harry Kirsch Chief Financial Officer Financial review and 2023 guidance 34 NOVARTIS Q4 RESULTS | FEBRUARY 1, 2023 | NOVARTIS INVESTOR PRESENTATION 34 Investor Relations │ Q4 2022 Results
Slide 35: 2022 financial results in line with guidance
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE 2022 financial results in line with guidance; ahead on Core OpInc Group full year guidance (Q3 earnings October 2022) In cc FY 2022 vs. PY Innovative Sales to grow mid single digit +4% Medicines Core OpInc
Slide 36: Consistent top-line growth and core margin expansion for Innovative Medicines
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE 2022 performance continues our track record of consistent top-line growth and core margin expansion for Innovative Medicines (IM) IM Sales1 IM Core OpInc1 IM Core Margin1 USD bn, % CAGR cc USD bn, % CAGR cc
Slide 37: Solid Q4 and FY performance
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE Solid Q4 and FY performance Change vs. PY Change vs. PY Group1 Q4 FY USD million 2022 % USD % cc 2022 % USD % cc Net Sales 12,690 -4 3 50,545 -2 4 Core Operating income 4,030 6 15 16,665 0 8 Operating incom
Slide 38: 26th consecutive dividend increase proposed: CHF 3.20 per share
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE Novartis proposes 26th consecutive dividend increase to the AGM: 3.20 CHF / share1 2022 proposal: CHF 3.20 / USD 3.464 2022 2021: CHF dividend USD dividend4 CHF 3.10 / USD 3.334 Dividend yield 3.8%2 3.5 Div
Slide 39: Continuing core margin improvements for Group driven by IM
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE Continuing core margin improvements for Group driven by IM Q4 2022 FY 2022 Core operating Core operating Net sales Core margin Net sales Core margin income Core margin income Core margin change vs. PY chang
Slide 40: Sandoz returns to growth in 2022; spin-off on track for H2
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE Sandoz returns to growth in 2022; planned spin-off on track for H2 Driven by Biopharma and ex-US sales FY performance1 Key growth drivers On track for planned for 2023 and beyond spin-off in H2 2023 Sales U
Slide 41: Novartis excluding and including Sandoz 2023 guidance
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE Novartis excluding and including Sandoz 2023 full year guidance Expected, barring unforeseen events; growth vs. PY in cc Sales expected to grow low-to-mid single digit Innovative Medicines (IM) Core OpInc e
Slide 42: Sandoz 2023 and mid-term guidance
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE Sandoz 2023 and mid-term guidance Expected, barring unforeseen events; growth vs. PY in cc Sales expected to grow low-to-mid single digit 2023 Core OpInc expected to decline low double digit, reflecting req
Slide 43: FY 2023 guidance on other financial KPIs
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE FY 2023 guidance on other financial KPIs Barring unforeseen events; (in cc) Group | Full year guidance Core Net Expenses expected to be broadly in line vs. 2022 Financial Result Core Tax Rate Expected to be
Slide 44: 2023 key drivers of Group core operating income
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE Group Core OpInc to grow mid single digit as sales growth and SG&A savings partly offset by Gx erosion and Sandoz stand-up costs 2023 key drivers of core operating income (Group) Vs. PY (cc) Illustrative +
Slide 45: Expected currency impact for 2023
Company overview Financial review Financial review 2023 priorities Appendix FINANCIAL PROFILE Expected currency impact for 2023 Currency impact vs. PY %pts, assuming late-January exchange rates prevail in 2023 FX impact on net sales FX impact on core operating income 0 to +1 -1 -3 to -4 -5 -7 -6 -9
Slide 46: 2023 priorities
Company overview Financial review 2023 2023 priorities priorities Appendix Vas Narasimhan, M.D. Chief Executive Officer 46 NOVARTIS Q4 RESULTS | FEBRUARY 1, 2023 | NOVARTIS MEDIA PRESENTATION 46 Investor Relations │ Q4 2022 Results
Slide 47: Creating impact by fulfilling unmet medical need
Company overview Financial review 2023 2023 priorities priorities Appendix Creating impact through fulfilling unmet medical need by delivering innovative medicines to as many people possible ~290 million patients reached ~40 new drug approvals with Innovative Medicines and over the last 20 years, de
Slide 48: Novartis priorities for 2023 and beyond
Company overview Financial review 2023 2023 priorities priorities Appendix CONCLUSION Novartis priorities for 2023 and beyond 1 Transforming to a pure-play IM company Prioritizing pipeline in specific DAs to high-value NMEs across our 5 core TAs 5 2 Focusing on 5 core TAs, technology platforms and t
Slide 49: Appendix
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Appendix 49 Investor Relations │ Q4 2022 Results
Slide 50: 2022 events
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations 2022 events1 ✓ Achieved to plan ✕ Not achieved to plan NME Lead Regulatory H1 Pluvicto™ mCRPC (US ✓ /EU ✓) Other readouts H1 sabat
Slide 51: 2023 expected key events
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations INNOVATION 2023 expected key events H1 2023 H2 2023 Regulatory Cosentyx HS ® EU US decisions Cosentyx® 2 ml AI US Cosentyx IV ® US
Slide 52: Our pipeline projects at a glance
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Our pipeline projects at a glance Phase 1/2 Phase 3 Registration Total Innovative Medicines 100 42 8 150 Solid Tumors 24 15 3 42 H
Slide 53: Novartis pipeline in Phase 1
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis pipeline in Phase 1 30 lead indications Lead indication Solid tumors Hematology Code Name Mechanism Indication(s) Code Na
Slide 54: Novartis pipeline in Phase 2
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis pipeline in Phase 2 28 lead indications Lead indication Solid Tumors Hematology Code Name Mechanism Indication(s) Code Na
Slide 55: Novartis pipeline in Phase 3
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis pipeline in Phase 3 8 lead indications Lead indication Solid Tumors Hematology Code Name Mechanism Indication(s) Code Nam
Slide 56: Novartis pipeline in registration
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis pipeline in registration 1 lead indication Lead indication Solid Tumors Cardiovascular Code Name Mechanism Indication(s)
Slide 57: Novartis submission schedule: New Molecular Entities
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis submission schedule New Molecular Entities: Lead and supplementary indications Cardiovascular Immunology Neuroscience Sol
Slide 58: Submission schedule: supplementary indications for existing brands
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Innovation: Pipeline overview Pipeline overview Innovation: Clinical trials Abbreviations Novartis submission schedule Supplementary indications for existing brands Cardiovascular Immunology Neuroscience Solid tumors Hem
Slide 59: Clinical Trials Update
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Clinical Trials Update Includes selected ongoing or recently concluded global
Slide 60: Cardiovascular
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cardiovascular 60 Investor Relations │ Q4 2022 Results
Slide 61: iptacopan - CFB inhibitor (APPLAUSE-IgAN)
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor NCT04578834 APPLAUSE-IgAN (CLNP023A2301) Indication
Slide 62: iptacopan - C3 glomerulopathy trials
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor iptacopan - CFB inhibitor NCT03955445 (CLNP023B12001
Slide 63: Leqvio - ORION-4 and ORION-8
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) NC
Slide 64: Leqvio - ORION-16 and ORION-13
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio® - siRNA (regulation of LDL-C) NC
Slide 65: Leqvio - VICTORION-2P
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) NCT05030428 VICTORION-2P (CKJX839B12302)
Slide 66: pelacarsen - Lp(a)HORIZON
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other pelacarsen - Antisense oligonucleotide (ASO) targeting Lp(a) NCT04023552 Lp(a)
Slide 67: XXB750 - NPR1 agonist
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other XXB750 - NPR1 agonist NCT05562934 (CXXB750B12201) Indication Hypertension Phas
Slide 68: Immunology
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Immunology 68 Investor Relations │ Q4 2022 Results
Slide 69: Cosentyx - SELUNE and GCAPTAIN
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A inhibitor NCT04181762 SELUNE (
Slide 70: ianalumab - AMBER and SIRIUS-LN
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor NCT03217422 AMBER (C
Slide 71: ianalumab - NEPTUNUS-2 and NEPTUNUS-1
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R inhibitor NCT05349214 NEPTUNUS
Slide 72: iscalimab - CD40 inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iscalimab - CD40 inhibitor NCT03905525 TWINSS (CCFZ533B2201) Indication Sjögre
Slide 73: ligelizumab - IgE inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ligelizumab - IgE Inhibitor NCT04984876 (CQGE031G12301) Indication Food allerg
Slide 74: LNA043 - ANGPTL3 agonist
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other LNA043 - ANGPTL3 agonist NCT04864392 ONWARDS (CLNA043A12202) Indication Knee o
Slide 75: remibrutinib - REMIX-1 and REMIX-2
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor NCT05030311 REMIX-1
Slide 76: Neuroscience
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Neuroscience 76 Investor Relations │ Q4 2022 Results
Slide 77: Mayzent - S1P1,5 receptor modulator
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Mayzent® - S1P1,5 receptor modulator NCT04926818 NEOS (CBAF312D2301) Indicatio
Slide 78: MIJ821 - NR2B negative allosteric modulator
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other MIJ821 - NR2B negative allosteric modulator (NAM) NCT04722666 (CMIJ821A12201)
Slide 79: remibrutinib - REMODEL-1 and REMODEL-2
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor remibrutinib - BTK inhibitor NCT05147220 REMODEL-
Slide 80: Zolgensma - STEER and STRENGTH
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Zolgensma® - SMN1 gene replacement therapy Zolgensma® - SMN1 gene replacement
Slide 81: Oncology
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Oncology 81 Investor Relations │ Q4 2022 Results
Slide 82: ianalumab - VAYHIT1 and VAYHIT2
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor NCT05653349 VAYHIT1 (CVAY736I12301) NCT05653219 V
Slide 83: ianalumab - VAYHIA
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor NCT05648968 VAYHIA (CVAY736O12301) Indication War
Slide 84: iptacopan - APPELHUS
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor NCT04889430 APPELHUS (CLNP023F12301) Indication Atyp
Slide 85: Jakavi - REACH4 and REACH5
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Jakavi® - JAK1/2 inhibitor Jakavi® - JAK1/2 inhibitor NCT03491215 REACH4 (CINC
Slide 86: JDQ443 - KRAS inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other JDQ443 - KRAS inhibitor NCT05132075 KontRASt-02 (CJDQ443B12301) Indication Non
Slide 87: Kisqali - NATALEE
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Kisqali® - CDK4 inhibitor NCT03701334 NATALEE (CLEE011O12301C) Indication Adju
Slide 88: NIS793 - TGFβ inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other NIS793 - TGFβ inhibitor NCT04935359 daNIS-2 (CNIS793B12301) Indication 1L meta
Slide 89: Piqray - PI3K-alpha inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Piqray® - PI3K-alpha inhibitor NCT04729387 EPIK-O (CBYL719K12301) Indication O
Slide 90: Pluvicto - PSMAfore and PSMAddition
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Pluvicto® - Radioligand therapy target PSMA Pluvicto® - Radioligand therapy ta
Slide 91: Rydapt - Multi-targeted kinase inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Rydapt® - Multi-targeted kinase inhibitor NCT03591510 (CPKC412A2218) Indicatio
Slide 92: sabatolimab - TIM3 antagonist
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other sabatolimab - TIM3 antagonist sabatolimab - TIM3 antagonist NCT04150029 STIMUL
Slide 93: Scemblix - ASC4FIRST
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Scemblix® - BCR-ABL inhibitor NCT04971226 ASC4FIRST (CABL001J12301) Indication
Slide 94: TNO155 - SHP2 inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other TNO155 - SHP2 inhibitor NCT03114319 (CTNO155X2101) Indication Solid tumors (si
Slide 95: Other
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars Other 95 Investor Relations │ Q4 2022
Slide 96: Ophthalmology
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Biosimilars Ophthalmology 96 Investo
Slide 97: Beovu - VEGF inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Biosimilars Beovu® - VEGF Inhibitor
Slide 98: libvatrep - TRPV1 antagonist
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Biosimilars libvatrep - TRPV1 antago
Slide 99: Global Health
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimilars Global Health 99 Investo
Slide 100: Adakveo - P-selectin inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimilars Adakveo® - P-selectin in
Slide 101: cipargamin - PfATP4 inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimilars cipargamin - PfATP4 inhi
Slide 102: Coartem - artemisinin combination therapy
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimilars Coartem® - PGH-1 (artemi
Slide 103: ganaplacide - non-artemisinin inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Health Biosimilars ganaplacide - Non-artemi
Slide 104: Biosimilars
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars Biosimilars 104 Investor Relations │ Q
Slide 105: aflibercept - VEGF inhibitor
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Biosimilars aflibercept - VEGF inhibitor NCT048648
Slide 106: Abbreviations
Company overview Financial review 2023 priorities Appendix Appendix Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Abbreviations Abbreviations AI Auto-injector IgAN IgA nephropathy AIH Autoimmune hepatitis IPF Idiopathic pulmonary fibrosis aHUS atypical Hemolytic Uremic Synd